Cargando…
Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
SIMPLE SUMMARY: Endocrine therapy targeted against estrogen and the estrogen receptor is the main treatment modality for luminal breast cancer. Although a majority of patients respond to this treatment, one-third of all patients are resistant to this therapy. Hyperactive estrogen receptor along with...
Autores principales: | Gandhi, Nishant, Oturkar, Chetan C., Das, Gokul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306694/ https://www.ncbi.nlm.nih.gov/pubmed/34298826 http://dx.doi.org/10.3390/cancers13143612 |
Ejemplares similares
-
Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
por: Oturkar, Chetan C., et al.
Publicado: (2022) -
Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK
por: Su, Yuan, et al.
Publicado: (2019) -
Coordination of the AMPK, Akt, mTOR, and p53 Pathways under Glucose Starvation
por: Zhou, Yifan, et al.
Publicado: (2022) -
AMPK–mTOR Signaling and Cellular Adaptations in Hypoxia
por: Chun, Yoomi, et al.
Publicado: (2021) -
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
por: Mukhopadhyay, Utpal K, et al.
Publicado: (2019)